



Commercial/Healthcare Exchange PA Criteria

Effective: July 6, 2023

Prior Authorization: Veozah (fezolinetant)

Products Affected: Veozah (fezolinetant) oral tablets

Medication Description: VEOZAH™ is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. Neurokinin 3 (NK3) receptor antagonist that blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron to modulate neuronal activity in the thermoregulatory center.

Covered Uses: Treatment of moderate to severe vasomotor symptoms due to menopause.

Exclusion Criteria:

1. Known cirrhosis
2. Severe renal impairment or end-stage renal disease
3. Concomitant use with CYP1A2 inhibitors

Required Medical Information:

1. Diagnosis
2. Medical history
3. Past therapies tried and failed

Prescriber Restriction: None

Age Restriction: None

Coverage Duration: 12 months

Other Criteria:

Initial Approval Criteria

1. **Vasomotor Symptoms of Menopause**
 - A. Patient must be a perimenopausal or post-menopausal female; **AND**
 - B. The provider attests to monitoring liver function tests (LFTs) prior to administration, at 3 months, 6 months, and 9 months after starting therapy; **AND**
 - C. Patient must not have cirrhosis; **AND**
 - D. Patient must not have severe renal impairment or end-stage renal disease; **AND**
 - E. The medication must not be used concomitantly with CYP1A2 inhibitors; **AND**
 - F. Patient must have tried and failed, or have contraindications to at least ONE menopausal hormone therapy; **AND**
 - G. Patient must have tried and failed, or have contraindications to at least ONE nonhormonal therapy (such as SSRI, SNRI, gabapentin, oxybutynin etc.)

June 2023



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Page 1 of 2



References:

1. Product Information: Veozah™ oral capsules, fezolinetant oral tablets. Astellas Pharma, Inc (per FDA), Northbrook, IL. 2023.

Policy Revision history

| Rev # | Type of Change | Summary of Change | Sections Affected | Date |
|--------------|-----------------------|--------------------------|--------------------------|-------------|
| 1 | New Policy | New Policy | All | 07/06/2023 |

